News for RAPT Therapeutics, Inc. (RAPT)

SOUTH SAN FRANCISCO, Calif., March 07, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. ( RAPT), a clinical-stage, immunology-based biopharmaceutical company

**media[559087]**

RAPT Therapeutics pivoted from a failed inflammation asset (RPT193) to focus on RPT904 for food allergies. Find out whether RAPT stock is a buy.

On December 31, 2024, Redmile Group, LLC (Trades, Portfolio) executed a significant stock transaction by acquiring an additional 13,427,917 shares of RAPT Thera

On December 31, 2024, Orbimed Advisors LLC executed a notable transaction by acquiring 13,135,260 shares of RAPT Therapeutics Inc. This purchase marks a signifi

Transaction Overview On December 31, 2024, PERCEPTIVE ADVISORS LLC (Trades, Portfolio) made a significant move by acquiring 5,880,000 shares of RAPT Therapeutic

Rapt Therapeutics (RAPT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

On January 31, 2025, Vanguard Group Inc executed a significant transaction involving RAPT Therapeutics Inc, a clinical-stage biopharmaceutical company. The firm

On January 31, 2025, FMR LLC (Trades, Portfolio), a prominent investment firm, executed a substantial reduction in its holdings of RAPT Therapeutics Inc. The tr

Read about RAPT Therapeutics (RAPT) latest filing in this financial article.

**media[510774]**

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. ( RAPT), a clinical-stage, immunology-based biopharmaceutical company f

RAPT Therapeutics (RAPT) stock gained after a licensing deal with Shanghai Jemincare for allergy drug JYB1904 led to H.C. Wainwright's upgrade. Read more here.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please ...

ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero

Capricor Therapeutics, Inc. (CAPR) experienced a significant stock price increase of 5.05%, reaching $13.73 per share with a trading volume of 406,112 shares. T

U.S. stocks traded mixed this morning, with the Dow Jones index falling around 150 points on Monday. Following the market opening Monday, the Dow traded down 0...

California BanCorp. (BCAL), headquartered in San Diego, California is up over 33 percent in Thursday's pre-market trading. The following are some of the other stocks making big moves in Thursday's pre-market trading.

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.69%